Invikafusp Achieves 59.3% Disease Control in Advanced Solid Tumor Trial
Early-phase clinical trials showed the novel dual T-cell agonist invikafusp was well-tolerated and achieved a 59.3% disease control rate in ...
Early-phase clinical trials showed the novel dual T-cell agonist invikafusp was well-tolerated and achieved a 59.3% disease control rate in ...
A first-in-human phase Ia trial reports that the covalent TEAD palmitoylation inhibitor BPI-460372 showed preliminary antitumor activity in advanced solid ...
Insilico Medicine plans to present first human Phase 1 data for the AI-designed pan-TEAD inhibitor ISM6331 in mesothelioma and other ...
A phase I trial found that the IAP antagonist tolinapant combined with pembrolizumab was well tolerated and produced a 33 ...
In a groundbreaking advancement that promises to reshape the landscape of cancer therapy, researchers have unveiled the first-in-human Phase 1 ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.